PREdiabetes GLycemic Impact and Data Evaluation (PRE-GLIDE)

Evaluation of the Impact of Continuous Glucose Monitoring (CGM) Systems on Glycemic Control in People With Prediabetes: Postmarketing Clinical Study

This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.

Study Overview

• Status: Recruiting
• Conditions: Insulin Resistance; Obesity & Overweight; Pre Diabetic
• Intervention / Treatment: Device: CGM Sibionics; Device: On-Call Extra Glucometer

Detailed Description

Prediabetes is considered a critical stage at which effective prevention of the development of diabetes is possible, provided that early detection and adequate glycemic control. International clinical guidelines and multicenter studies suggest that early intensive glycemic control is associated with a better prognosis and a reduced risk of complications. However, standard self-monitoring has limited information on glycemic variability, which is especially important in the early stages of carbohydrate metabolism disorders, including prediabetes. Routine indicators such as fasting blood glucose, 1 and 2 hours after a meal, and glycated hemoglobin (HbA1c) do not always clearly differentiate between diabetes, prediabetes, and normal carbohydrate metabolism. Recently, there has been a need for more comprehensive blood glucose monitoring strategies that cover the entire spectrum of glycemic variability. Continuous glucose monitoring (CGMs) technology provides real-time glucose concentration data, overcoming the limitations of traditional monitoring methods. Recently, not only among people with diabetes, but also among people with prediabetes, there has been an increasing trend towards using CGM as a personal device to monitor glucose levels and promote healthy habits such as increased activity, diet, and sleep. Their motivation is to improve their own glycemic control and avoid the future development of diabetes and its associated complications, to optimize blood glucose levels to achieve peak mental or physical performance, and to use personal monitoring data to develop sustainable behavioral skills. The contactless 24-hour monitoring system is considered a promising tool for personalized glycemic control, but its use in people with prediabetes has not been studied enough This is a prospective, open-label, randomized controlled trial involving 80 adult patients with prediabetes recruited at the Bogomolets National Medical University. Participants were randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring (CGM group) or the control group (standard Self-Monitoring of Blood Glucose [SMBG] using conventional glucometers). Participants will undergo a 3-month observation period. The use of the assigned monitoring devices (CGM or SMBG glucometer) and pedometers will last for the first 1 month. The study consists of three visits: Visit 1 (baseline), Visit 2 (1 month, end of intervention), and Visit 3 (3 months, follow-up period). During these visits, researchers will collect data on glycated hemoglobin (HbA1c), fructosamine, Cpeptide, HOMA-IR index, lipid profile, anthropometric indicators (body mass index (BMI), waist circumference), bioimpedance measurement, physical activity monitoring using pedometers, and SF-36 questionnaire to assess quality of life.

The gathered data will help determine whether continuous monitoring provided by CGM systems improves glycemic control and increases patient adherence to lifestyle changes compared to conventional SMBG methods.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nazarii Kobyliak, Professor; Phone Number: +380442356005; Email: nazariikobyliak@gmail.com
• Study Contact Backup: Name: Ilona Rudneva, Dr; Phone Number: 0442356005; Email: ilonarudneva57@gmail.com

Study Locations

• Ukraine
  • Kyiv, Ukraine, 01601
    • Recruiting
    • Bogomolets National Medical University
    • Contact: Nazarii Kobyliak, Professor; Phone Number: 0442356005; Email: nazariikobyliak@gmail.com
    • Contact: Victoriia Yerokhovych, PhD; Email: ilonarudneva57@gmail.com
  • Kyiv, Ukraine, 01601
    • Recruiting
    • University Hospital of Bogomolets National Medical University
    • Contact: Ilona Rudneva, PhD student; Phone Number: 0442356005; Email: ilonarudneva57@gmail.com
    • Contact: Ieva Ilkiv, PhD Student; Phone Number: 0442356005; Email: evailkiv333@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age of 18 years and older.
• Presence of prediabetes diagnosed according to criteria of the American Diabetes Association
• Persons who treated with diet and exercise alone or metformin on a stabilized dose for at least 3 months before the study;
• Ability to comply with protocol requirements and maintain a patient diary.
• Signed informed consent.

Exclusion Criteria:

• Presence of type 1 or type 2 diabetes;
• Decompensated liver or kidney diseases (GFR < 45 ml/min/1. 73 m²);
• Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study;
• Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia;
• Pregnancy or lactation;
• Mental or cognitive impairments that would interfere with study participation;
• Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months;
• Recent use of any CGM within the last 12 months;
• Known allergy to sensor materials;
• Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant;
• Participation in another clinical study within the last 3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CGM group; Participants with prediabetes will be provided with a Real-Time Continuous Glucose Monitoring (RT-CGM) device to monitor their blood glucose along with educational materials to better understand and manage their prediabetes and other supporting services. Pre and post intervention surveys and investigation will be implemented. Participants will be utilizing RT-CGM device for 28 days and then followed up for 3-month participation.	Device: CGM Sibionics; A registered medical device for real-time monitoring of glucose levels in interstitial fluid.
Active Comparator: traditional fingerstick glucometer; Participants with prediabetes will be provided with traditional fingerstick glucometer device to self-monitor their blood glucose along with educational materials to better understand and manage their prediabetes and other supporting services. Pre and post intervention surveys and investigation will be implemented. Participants will be utilizing glucometer with at least 2-3 measurements per week for 28 days and then followed up for 3-month participation.	Device: On-Call Extra Glucometer; Capillary glucose monitoring using fingerstick glucometer as per standard care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in HbA1c level	HbA1c in %	at 3 month (end of follow-up period)
Changes in Fructosamine level	Fructosamine in μmol/L	at 3 month (end of intervention period)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HOMA-2IR	This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php	at 3 month (follow-up period) compared to baseline
insulin sensitivity (%S)	This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php	at 3 month (follow-up period) compared to baseline
β-cell function (%B)	This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php	at 3 month (follow-up period) compared to baseline
body mass index (BMI)	weight in kg and height in meters will be combined to report BMI in kg/m^2	at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
waist circumferences (WC)	WC in cm	at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
visceral fat content	visceral fat content using electronic scales-analyzers of body composition Huawei (Smart Scale series 3/3 Pro	at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
Total Cholesterol (TC)	TC in mmol/l	at 3 month (follow-up period) compared to baseline
Tryglicerides (TG)	TG in mmol/l	at 3 month (follow-up period) compared to baseline
LDL-Cholesterol (LDL-C)	LDL-C in mmol/l	at 3 month (follow-up period) compared to baseline]
Physical activity levels	Daily number of steps as measured by a sealed pedometer	at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
quality-of-life evaluation	Self-efficacy questionnaire SF-36 (Medical Outcomes Study Short-Form 36).	at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline

Collaborators and Investigators

• Sponsor: Nazarii Kobyliak
• Collaborators: COR-Medical LLC; Iridium LLC
• Investigators: Principal Investigator: Nazarii Kobyliak, Bogomolets National Medical University

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): January 31, 2027

Study Registration Dates

• First Submitted: May 14, 2026
• First Submitted That Met QC Criteria: May 14, 2026
• First Posted (Actual): May 20, 2026

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: obesity; insulin resistance; prediabetes; continuous glucose monitoring; traditional glycemia self-monitoring
• Additional Relevant MeSH Terms: Endocrine System Diseases; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Diabetes Mellitus; Hyperinsulinism; Hyperglycemia; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Insulin Resistance; Prediabetic State; Glucose Intolerance
• Other Study ID Numbers: PRE-GLIDE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No